Agonist antibodies targeting CD137 are potent inducers of tumor-reactive T cell proliferation, cytokine production and cytotoxicity, and have been explored clinically for their ability to enhance immune cell-mediated destruction of tumor cells. Here, TNFRSF9 is linked to neoplasm.